BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahsan A, Hiniker SM, Davis MA, Lawrence TS, Nyati MK. Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res 2009;69:5108-14. [PMID: 19509222 DOI: 10.1158/0008-5472.CAN-09-0466] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Wu P, Wee P, Jiang J, Chen X, Wang Z. Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation. PLoS One 2012;7:e41354. [PMID: 22984397 DOI: 10.1371/journal.pone.0041354] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
2 Cuneo KC, Nyati MK, Ray D, Lawrence TS. EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther 2015;154:67-77. [PMID: 26205191 DOI: 10.1016/j.pharmthera.2015.07.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
3 Yu CH, Chou CC, Tu HF, Huang WC, Ho YY, Khoo KH, Lee MS, Chang GD. Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. Oncotarget 2018;9:21512-29. [PMID: 29765556 DOI: 10.18632/oncotarget.25177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
4 Ahsan A, Ramanand SG, Bergin IL, Zhao L, Whitehead CE, Rehemtulla A, Ray D, Pratt WB, Lawrence TS, Nyati MK. Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts. Neoplasia 2014;16:105-14. [PMID: 24709418 DOI: 10.1593/neo.14182] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
5 Luo LL, Zhao L, Wang YX, Tian XP, Xi M, Shen JX, He LR, Li QQ, Liu SL, Zhang P, Xie D, Liu MZ. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma. Sci Rep. 2015;5:17336. [PMID: 26670461 DOI: 10.1038/srep17336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
6 Ray P, Raghunathan K, Ahsan A, Allam US, Shukla S, Basrur V, Veatch S, Lawrence TS, Nyati MK, Ray D. Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance. J Biol Chem 2020;295:12661-73. [PMID: 32669362 DOI: 10.1074/jbc.RA120.013519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang Q, Gavin W, Masiello N, Tran KB, Laible G, Shepherd PR. Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models. Biotechnol Rep (Amst) 2020;28:e00533. [PMID: 33024714 DOI: 10.1016/j.btre.2020.e00533] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Ahsan A, Ray D, Ramanand SG, Hegde A, Whitehead C, Rehemtulla A, Morishima Y, Pratt WB, Osawa Y, Lawrence TS, Nyati MK. Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. J Biol Chem 2013;288:26879-86. [PMID: 23897823 DOI: 10.1074/jbc.M113.492280] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
9 Corsi L, Mescola A, Alessandrini A. Glutamate Receptors and Glioblastoma Multiforme: An Old "Route" for New Perspectives. Int J Mol Sci 2019;20:E1796. [PMID: 30978987 DOI: 10.3390/ijms20071796] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
10 Ray P, Tan YS, Somnay V, Mehta R, Sitto M, Ahsan A, Nyati S, Naughton JP, Bridges A, Zhao L, Rehemtulla A, Lawrence TS, Ray D, Nyati MK. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors. Oncotarget 2016;7:68597-613. [PMID: 27612423 DOI: 10.18632/oncotarget.11860] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Clifford R, Govindarajah N, Parsons JL, Gollins S, West NP, Vimalachandran D. Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. Br J Surg 2018;105:1553-72. [PMID: 30311641 DOI: 10.1002/bjs.10993] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
12 Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N, Schumann TE, Jing X, Menawat R, Tomlins SA, Zheng H, Otte AP, Mehra R, Siddiqui J, Dhanasekaran SM, Nyati MK, Pienta KJ, Palanisamy N, Kunju LP, Rubin MA, Chinnaiyan AM, Varambally S. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia 2012;14:905-14. [PMID: 23097625 DOI: 10.1593/neo.121192] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
13 Mierzwa ML, Nyati MK, Morgan MA, Lawrence TS. Recent advances in combined modality therapy. Oncologist 2010;15:372-81. [PMID: 20413642 DOI: 10.1634/theoncologist.2009-S105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, Nyati MK. Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. Neoplasia 2011;13:570-8. [PMID: 21750651 DOI: 10.1593/neo.11632] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
15 Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, Ray D, Lawrence TS, Nyati MK. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 2012;14:670-7. [PMID: 22952420 DOI: 10.1593/neo.12986] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.7] [Reference Citation Analysis]
16 Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Chaudhry MA, Wahl R, Forastiere A, Gillison M. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin Cancer Res 2012;18:1735-42. [PMID: 22271880 DOI: 10.1158/1078-0432.CCR-11-2544] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
17 Mao J, Ma L, Shen Y, Zhu K, Zhang R, Xi W, Ruan Z, Luo C, Chen Z, Xi X, Chen S. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer. Cell Death Dis 2018;9:963. [PMID: 30237564 DOI: 10.1038/s41419-018-0998-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
18 Jian Z, Strait A, Jimeno A, Wang XJ. Cancer Stem Cells in Squamous Cell Carcinoma. J Invest Dermatol 2017;137:31-7. [PMID: 27638386 DOI: 10.1016/j.jid.2016.07.033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
19 Chen X, Wu H, Chen H, Wang Q, Xie XJ, Shen J. Astragaloside VI Promotes Neural Stem Cell Proliferation and Enhances Neurological Function Recovery in Transient Cerebral Ischemic Injury via Activating EGFR/MAPK Signaling Cascades. Mol Neurobiol 2019;56:3053-67. [PMID: 30088176 DOI: 10.1007/s12035-018-1294-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
20 Tsien CI, Nyati MK, Ahsan A, Ramanand SG, Chepeha DB, Worden FP, Helman JI, D'Silva N, Bradford CR, Wolf GT, Lawrence TS, Eisbruch A. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head Neck 2013;35:1323-30. [PMID: 22907806 DOI: 10.1002/hed.23128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]